

**TREATMENTTRENDS®: MULTIPLE SCLEROSIS**

*This series of quarterly reports examines the current trends in the management of multiple sclerosis (MS) from the perspective of neurologists. TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends® evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.*

**SAMPLE FRAME AND METHODOLOGY**

45 minute online quantitative survey with several open ended questions for qualitative feedback

- 100+ respondents surveyed in Waves 1 through 3
- 200+ respondents in Wave 4

To qualify, respondents must meet the following criteria:

- Minimum of 50 MS patients under management
- Have been in practice a minimum of 2 years and a maximum of 30 years
- More than 50% of professional time spent in clinical practice

**PRODUCT COVERAGE**

Approved: Avonex, Betaseron, Copaxone, Extavia, Gilenya, Rebif, Tysabri, Ampyra, Nuedexta

In development: alemtuzumab, BG-12, daclizumab, laquinimod, ocrelizumab, pegylated IFN-β-1a, teriflunomide, arbaclofen placarbil, IPX056, Sativex

**RELATED 2011 REPORTS**

TreatmentTrends®: Multiple Sclerosis (EU)  
ChartTrends®: Multiple Sclerosis (US)  
ChartTrends®: Multiple Sclerosis (EU)  
PatientTrends: Multiple Sclerosis  
Treatment Algorithms: Multiple Sclerosis  
LaunchTrends®: Gilenya

**PRICE**

\$72,000 for quarterly report bundle  
\$24,500 for Q1-Q3 single report  
\$40,000 for Q4 single report

**PROJECT OBJECTIVES**


- Understand the relative MS patient load by disease classification (CIS, RRMS, PRMS, SPMS, PPMS) and how DMAs are used in each group
- Understand product attributes that are most important to neurologists when selecting DMAs and compare the different brands on how they are perceived to perform against each attribute
- Understand how the use of each DMA brand is expected to change in the next six months and what factors are driving those trends
- Evaluate sales and messaging efforts of DMA therapies
- Assess awareness of and interest in DMA therapies that are in late stage development

**DELIVERABLES**

- Final report in PowerPoint format
  - Tracking between waves will be provided for clients purchasing the report series
  - If client is also purchasing TreatmentTrends®: Multiple Sclerosis (EU), then the analysis between the regions (US/EU) will also be included
- Complete set of frequency tables, summary statistics, and cross tabulations
- Proprietary question slide deck and frequency tables
  - Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each wave


**REPORT DATES AND PRICING**

Waves	Date comments/proprietary questions are due	Field date	Publication date
1	February 7, 2011	February 17, 2011	March 24, 2011
2	May 2, 2011	May 12, 2011	June 16, 2011
3	August 1, 2011	August 11, 2011	September 15, 2011
4	October 25, 2011	November 4, 2011	December 16, 2011



**TABLE OF CONTENTS**

Introduction.....	4
Market Background	
Market News	
Methodology	
Research Objectives	
Executive Summary.....	20
Respondent Demographics.....	30
Respondent Demographics	
Primary Conditions Treated	
Improved Therapy Need Across Neurology Indications	
Current Medical Practice.....	34
Recent Changes in Management/Treatment of MS patients	
Patients by MS Disease Classification	
Current Use of DMAs in MS.....	37
DMA Treatment Prevalence	
Reasons for Not Prescribing a DMA	
Clinical Experience with Specific DMAs	
Current DMA Allocation	
Preferred First, Second, and Third Line DMAs	
Most Likely Initiation of DMA by Patient Type	
Switching Patterns to DMA Therapies	
DMA Competitive Landscape.....	51
Overall Satisfaction with DMA Brands	
DMA Brand Overall Performance	
DMA Brand Relative Preference	
Physician Perception of Patient’s DMA Brand Preference	
Physician Perception of Patient’s Administration Preference	
Attribute Importance and Brand Perception	
Stated versus Derived Importance of Attributes	
Statement Agreement.....	65
DMA Promotional Messages.....	69
Detailing Frequency and Extent	
Unaided Main Message Topic of Recent DMA Detailing	
Aided Messages of Recent DMA Detailing	
Satisfaction with DMA Sales Representatives	
Patient Request for Specific DMA Brand	
Anticipated Use of DMAs in MS.....	77
Anticipated Versus Current DMA Treatment Prevalence	
Anticipated Versus Current DMA Brand Allocation	
Current versus Anticipated Gilenya Trial	
Major Obstacles to Increased Prescribing by DMA	



**TABLE OF CONTENTS CONTINUED**

Use of Symptomatic Agents in MS Patients: Current and Anticipated.....	85
Willingness to Prescribe Ampyra	
Current and Anticipated Ampyra Trial and Use	
Ampyra Patient Origination	
Reasons for Not Initiating Ampyra Trial	
Time to Initiate Ampyra Trial	
Ampyra Treatment Objectives	
Ampyra Discontinuation Rate and Reasons	
Overall Satisfaction with Ampyra	
Anticipated and Peak Ampyra Patient Share Growth	
Willingness to Prescribe Nuedexta	
Current Nuedexta Trial and Use	
Nuedexta Patient Origination	
Reasons for Not Initiating Nuedexta Trial	
Time to Initiate Nuedexta Trial	
Nuedexta Discontinuation Rate	
Overall Satisfaction with Nuedexta	
Anticipated and Peak Nuedexta Patient Share Growth	
DMA Products in Development.....	100
Relative Importance of Unmet Needs for DMA Development	
Unaided/Aided Awareness of DMAs in Development	
Familiarity of DMAs in Development	
Interest in DMAs in Development	
Anticipated Current DMA Replacement by DMAs in Development	
Perception of Clinical Value of DMAs in Development	
MS-Related Symptomatic Products in Development.....	109
Unaided/Aided Awareness of MS-Related Symptomatic Products	
Familiarity of MS-Related Symptomatic Products	
Interest in MS-Related Symptomatic Products	
Perception of Clinical Value of DMAs in Development	
Appendix .....	113